Connor Clark & Lunn Investment Management Ltd. Purchases New Shares in Elanco Animal Health Incorporated $ELAN

Connor Clark & Lunn Investment Management Ltd. purchased a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 95,381 shares of the company’s stock, valued at approximately $2,347,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. NewEdge Advisors LLC boosted its holdings in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Elanco Animal Health during the second quarter valued at approximately $38,000. Root Financial Partners LLC raised its holdings in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares during the period. Uniplan Investment Counsel Inc. purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $41,000. Finally, Torren Management LLC purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $46,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ELAN shares. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. JPMorgan Chase & Co. raised their target price on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. UBS Group lifted their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, TD Cowen upped their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $24.16 on Friday. The company’s 50 day moving average price is $24.62 and its 200 day moving average price is $24.01. Elanco Animal Health Incorporated has a 52 week low of $17.11 and a 52 week high of $27.98. The company has a market capitalization of $12.07 billion, a PE ratio of -58.93, a PEG ratio of 1.47 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Shiv O’neill acquired 3,998 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average cost of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the acquisition, the insider owned 87,832 shares in the company, valued at approximately $2,071,078.56. The trade was a 4.77% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence Erik Kurzius acquired 40,000 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, with a total value of $936,000.00. Following the transaction, the director owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. The trade was a 26.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 63,198 shares of company stock valued at $1,473,109 in the last three months. Company insiders own 1.14% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.